The FDA has been a little active recently and not only from changes but also from controversies. I think that some of the changes certainly could be seen as tailwinds but the increased variability of decisions and actions are perhaps more important. Even if announced changes are positive, when the industry has to make capital […]
February 11th Biotech Update
The still dominated by the metabolic franchise, with GLP-1s representing one of the largest value creation cycles in sector history. One has to think that the fate of this market plays a large part of generalist interest going forward. Shares of NOVO and LLY have been highly sensitive to competitive dynamics, supply constraints, and incremental […]
Strategic Analysis: LibertyStream Infrastructure (VLTLF) – The Modular Lithium Disruption
Chimera Research Group Critical Minerals Equity Note LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF) Company Achieves Consistent, Spec-Compliant Lithium Carbonate Production from Automated Refining Unit in the Texas Permian Basin. Author: Joe Gantos, Senior Analyst Date: February 01, 2026 Recommendation: STRONG BUY Target Price (12-18 mo): C$3.00 – C$5.00 Current Price: C$1.39 Market […]
January 23rd Biotech Update
The sector continues to plod along. I think there is some interesting news with the oral GLP launch and while it certainly has import for the companies involved, I think the sector does best when there is a big launch that creates buzz outside the sector. It is the generalists that really push bull markets […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
